Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapy–controlled, phase 2 multicenter study (ONE-BRIDGE)

Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapy–controlled, phase 2 multicenter study (ONE-BRIDGE)

Abstract Background Acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory lung injury with high mortality; no approved medication exists. Efficacy and safety of bone marrow–derived, allogeneic, multipotent adult progenitor cells (invimestrocel) plus standard treatment in pati...

Full description

Bibliographic Details
Main Authors: Kazuya Ichikado, Toru Kotani, Yasuhiro Kondoh, Hideaki Imanaka, Takeshi Johkoh, Kiminori Fujimoto, Shin Nunomiya, Tomotaka Kawayama, Masanori Sawada, Eric Jenkins, Sadatomo Tasaka, Satoru Hashimoto
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Stem Cell Research & Therapy
Subjects:
Acute respiratory distress syndrome
Lung injury
Mesenchymal stem cells
Pneumonia
Online Access:https://doi.org/10.1186/s13287-023-03451-z

Internet

https://doi.org/10.1186/s13287-023-03451-z

Similar Items